Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > W/e

<< Previous

Bullboard Posts

Next >>

Comment by Pandoraon Aug 16, 2021 11:52pm

200 Views

Post# 33715240

RE:RE:W/e

Rawrasaurus wrote: At some point, probably. I doubt it'll be at this price point though. I'm betting it rebounds and they raise or partner going into their actual p3.

Rar and Raw both having been here for a week or less and both promoting a financing?? One might even think they could be the same guy looking at the makeup of the names. But - who really cares - just a passing thought.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec